Showing 654 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

Hepatitis C treatment

HIV, HCV and TB Pipeline Report

Editor's pick
Treatment Action Group & i-Base
21 July 2014
Hepatitis C treatment

EU nations join forces against 'exorbitant' hepatitis C drug: France

Editor's pick
Medical Xpress
10 July 2014
New & experimental hepatitis C treatment

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen

Editor's pick
Bristol-Myers Squibb press release
8 July 2014
New & experimental hepatitis C treatment

Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

Editor's pick
Bristol-Myers Squibb press release
30 June 2014
New & experimental hepatitis C treatment

HCV drug out of the running

Editor's pick
MedPage Today
23 June 2014
New & experimental hepatitis C treatment

A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

Editor's pick
Reuters
23 June 2014
New & experimental hepatitis C treatment

UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

Editor's pick
CDC
19 June 2014
New & experimental hepatitis C treatment

AbbVie all-oral hepatitis C therapy gets rapid EU review

Editor's pick
Reuters
17 June 2014
New & experimental hepatitis C treatment

NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

Editor's pick
NICE press release
16 June 2014
Hepatitis C treatment

Low uptake of HCV treatment in England will lead to substantial disease burden by 2035

News
13 June 2014
New & experimental hepatitis C treatment

Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C

Editor's pick
Forbes
9 June 2014
New & experimental hepatitis C treatment

No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Editor's pick
NATAP
29 May 2014
New & experimental hepatitis C treatment

OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Editor's pick
Reuters
16 May 2014
New & experimental hepatitis C treatment

AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C

Editor's pick
AbbVie press release
8 May 2014
Hepatitis C treatment

Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation

News
8 May 2014
Hepatitis C treatment

Janssen submits US FDA new drug application for simeprevir / sofosbuvir combination use

Editor's pick
Janssen press release
8 May 2014
Access to healthcare

UNITAID approves grants of $160 million, for hepatitis C, MDR-TB and malaria drugs

Editor's pick
UNITAID
7 May 2014
Pharmaceutical industry

Biotech’s Hard Bargain

Editor's pick
The New Yorker
24 April 2014
New & experimental hepatitis C treatment

Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence

News
23 April 2014
New & experimental hepatitis C treatment

AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

Editor's pick
AbbVie press release
23 April 2014
New & experimental hepatitis C treatment

Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6

News
17 April 2014
Access to healthcare

NHS England agrees funding for life-saving hepatitis C drug

Editor's pick
NHS England (press release)
17 April 2014
New & experimental hepatitis C treatment

England: Patients with end-stage liver disease caused by hepatitis C to get new drug

Editor's pick
The Guardian
17 April 2014
New & experimental hepatitis C treatment

BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks

News
17 April 2014